J. Molner (MOLNR) H1 2024 earnings summary

Executive summary

• Revenue for the first six months of 2024 rose 382% year-over-year to €1,305,327, driven by US hydrocortisone butyrate sales and growth in analytical services in the US, Canada, and Europe.

• FDA approval was received for the first Estonian-developed ANDA in April 2024, with launch expected in Q4 2024; two more ANDAs and five licensed products are in the pipeline for US and Canadian markets.

• Canadian partner launched norepinephrine bitartrate in June 2024; one additional ANDS is under review by Health Canada.

Financial highlights

• Consolidated sales revenue reached €1,305,327, up from €270,769 in H1 2023.

• Consolidated loss widened to €982,119 from €444,526 year-over-year.

• Total assets increased 84% to €4,306,345 as of 30.06.2024; liabilities rose to €3,460,225 (80% of assets), and equity decreased to €846,120 (20% of assets).

• Investments in fixed assets totaled €481,683, with €358,589 allocated to R&D.

• Cash and cash equivalents at period end were €611,512, up from €92,522 at year-end 2023.

Outlook and guidance

• Launch of the FDA-approved product is anticipated in Q4 2024; two additional products are expected to return to the US market in H2 2024, with the remainder in 2025, pending regulatory approval.

• Continued focus on expanding the drug pipeline for the US and Canadian institutional sectors through in-licensing, development, and acquisition.